Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18180392 | 0.89 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1AOC3STAT6MAPT | |
| SCHEMBL21992683 | 0.82 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1AOC3STAT6MAPT | |
| SCHEMBL20007716 | 0.80 | PER2 (0.32) | — | |
| SCHEMBL20007132 | 0.80 | AOC3 (0.37) | HSP90AA1HSP90AB1AOC3MAPTGPR183 | |
| SCHEMBL19969131 | 0.78 | NR1H4 (0.40) | MAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL18180275 | 0.73 | CTSK (0.41) | HSP90AA1AOC3MAPT | |
| SCHEMBL19962141 | 0.72 | BACE1 (0.38) | HSP90AA1HSP90AB1AOC3STAT6MAPT | |
| SCHEMBL18317595 | 0.68 | CIT (0.39) | MAPTSMN1; SMN2 | |
| SCHEMBL18180401 | 0.68 | CIT (0.39) | MAPTSMN1; SMN2 | |
| SCHEMBL18179956 | 0.68 | CIT (0.37) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | HSP90AA1 2227/4885HSP90AB1 1599/4885AOC3 4284/4885 |
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | HSP90AA1 2227/4885HSP90AB1 1599/4885AOC3 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.